{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:17:36Z","timestamp":1793521056062,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2023-01807"],"award-info":[{"award-number":["2023-01807"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"US National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK115534"],"award-info":[{"award-number":["R01DK115534"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Swedish Heart and Lung Foundation","doi-asserted-by":"publisher","award":["20230371"],"award-info":[{"award-number":["20230371"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Region Stockholm","award":["FoUI-986028"],"award-info":[{"award-number":["FoUI-986028"]}]},{"name":"Martin Rind and Westman Foundations"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Inflammation and hyperlipidaemia play a pivotal role in atherosclerotic cardiovascular disease (ASCVD), and inflammatory risk may outweigh cholesterol risk among statin-treated patients. However, it is unclear how these risks relate to ASCVD outcomes in a real-world population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Observational study of 39 638 ASCVD adults in Stockholm\u2019s healthcare (2007\u201321) who underwent routine testing for high-sensitivity C-reactive protein (hsCRP) and low-density lipoprotein cholesterol (LDL-C). Groups were defined by LDL-C (\u22651.8 vs. &amp;lt; 1.8\u2005mmol\/L) and hsCRP (\u22652 vs. &amp;lt; 2\u2005mg\/L): as low risk, high cholesterol risk (CR) alone, high inflammatory risk (IR) alone, and combined high cholesterol and inflammatory risk (CIR). Primary outcome was major adverse cardiovascular (CV) events (MACE); secondary outcomes included all-cause death, CV death, and heart failure (HF) hospitalization. Mean age at baseline was 69 years, 61% were men, 19.4% had chronic kidney disease (CKD), and 61% were receiving lipid-lowering therapy (LLT). Over follow-up (median 4.5 years), 5349 MACE, 7955 deaths (2088 CV deaths) and 4286 HF hospitalizations occurred. Compared with patients with low risk, those with IR or CIR experienced the highest MACE risk (HR 1.39; 95% CI 1.26\u20131.54 for CIR, HR 1.18; 1.05\u20131.33 for IR), followed by CR (HR 1.12; 1.01\u20131.24). Elevated hsCRP, with or without elevated LDL-C, was strongly associated with secondary outcomes, while CR alone was not. Patterns were generally consistent across CKD and LLT subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In routine care high inflammatory risk, alone or with high cholesterol risk, is a stronger predictor of adverse outcomes than high cholesterol alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjopen\/oeag023","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:42:02Z","timestamp":1770986522000},"source":"Crossref","is-referenced-by-count":3,"title":["Inflammatory and cholesterol risks and rates of major cardiovascular events among patients with atherosclerotic cardiovascular disease in routine care"],"prefix":"10.1093","volume":"6","author":[{"given":"Faizan","family":"Mazhar","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Campus Solna, Karolinska Institutet, Nobels v\u00e4g 12A, 17165 Solna , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico \u2018G. Rodolico-San Marco\u2019, University of Catania , Via S.Sofia, 78 - 95123 Catania ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-275X","authenticated-orcid":false,"given":"Paul","family":"Hjemdahl","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Clinical Epidemiology\/Clinical Pharmacology, Karolinska Institutet and Karolinska University Hospital, Framstegsgatan, 171 64 Solna , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvid","family":"Sj\u00f6lander","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Campus Solna, Karolinska Institutet, Nobels v\u00e4g 12A, 17165 Solna , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Gerward","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , Vandt\u00e5rnsvej 108, 2860 S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Mathisen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , Vandt\u00e5rnsvej 108, 2860 S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Plunde","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S , Vandt\u00e5rnsvej 108, 2860 S\u00f8borg ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2975-6971","authenticated-orcid":false,"given":"Vijay","family":"Kunadian","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust , Newcastle upon Tyne NE1 7RU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-379X","authenticated-orcid":false,"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Entr\u00e9v\u00e4gen 2, 182 88 Danderyd , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan-Jesus","family":"Carrero","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Campus Solna, Karolinska Institutet, Nobels v\u00e4g 12A, 17165 Solna , Stockholm ,","place":["Sweden"]},{"name":"Division of Nephrology, Department of Clinical Sciences, Danderyd Hospital , Entr\u00e9v\u00e4gen 2, 182 88 Danderyd ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2026041617114949200_oeag023-B1","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American Heart Association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"2026041617114949200_oeag023-B2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B3","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"2026041617114949200_oeag023-B4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026041617114949200_oeag023-B5","doi-asserted-by":"crossref","first-page":"101063","DOI":"10.1016\/j.jacadv.2024.101063","article-title":"Interleukin-6 and cardiovascular events in healthy adults: MESA","volume":"3","author":"Khan","year":"2024","journal-title":"JACC Adv"},{"key":"2026041617114949200_oeag023-B6","doi-asserted-by":"crossref","first-page":"e005637","DOI":"10.1161\/JAHA.117.005637","article-title":"Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (stabilization of plaque using darapladib\u2014thrombolysis in myocardial infarction 52) Trial","volume":"6","author":"Fanola","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026041617114949200_oeag023-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjcard.2023.03.025","article-title":"C-Reactive Protein and risk of cardiovascular events and mortality in patients with various cardiovascular disease locations","volume":"197","author":"Burger","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026041617114949200_oeag023-B8","doi-asserted-by":"crossref","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) Trial","volume":"6","author":"Held","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026041617114949200_oeag023-B9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"2026041617114949200_oeag023-B10","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B11","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/joim.13418","article-title":"The Stockholm CREAtinine Measurements (SCREAM) project: fostering improvements in chronic kidney disease care","volume":"291","author":"Carrero","year":"2022","journal-title":"J Intern Med"},{"key":"2026041617114949200_oeag023-B13","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B14","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2026041617114949200_oeag023-B15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-023-01826-3","article-title":"Effect of dual residual risk of cholesterol and inflammation on all-cause mortality in patients with cardiovascular disease","volume":"22","author":"Yang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2026041617114949200_oeag023-B16","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026041617114949200_oeag023-B17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2026041617114949200_oeag023-B18","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B19","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B21","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"key":"2026041617114949200_oeag023-B22","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"2026041617114949200_oeag023-B23","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1093\/eurheartj\/ehaf281","article-title":"LDL-cholesterol, lipoprotein(a) and high-sensitivity low-density lipoprotein cholesterol, lipoprotein(a) and high-sensitivity C-reactive protein are independent predictors of cardiovascular events","volume":"46","author":"Markus","year":"2025","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B24","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/eurheartj\/ehad867","article-title":"C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project","volume":"45","author":"Arnold","year":"2024","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B25","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/eurheartj\/ehaf196","article-title":"Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention","volume":"46","author":"Bay","year":"2025","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ahj.2022.05.021","article-title":"Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease","volume":"251","author":"Mazhar","year":"2022","journal-title":"Am Heart J"},{"key":"2026041617114949200_oeag023-B27","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/bcp.14333","article-title":"Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study","volume":"86","author":"Rezende Macedo do Nascimento","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2026041617114949200_oeag023-B28","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1093\/eurheartj\/ehad241","article-title":"Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?","volume":"44","author":"Liuzzo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.3390\/biom14111393","article-title":"The dual burden: exploring cardiovascular complications in chronic kidney disease","volume":"14","author":"Caturano","year":"2024","journal-title":"Biomolecules"},{"key":"2026041617114949200_oeag023-B30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2002.00637.x","article-title":"Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?","volume":"62","author":"Stenvinkel","year":"2002","journal-title":"Kidney Int"},{"key":"2026041617114949200_oeag023-B31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1046\/j.1525-139X.2003.16023.x","article-title":"The clinical epidemiology of cardiovascular diseases in chronic kidney disease: cardiovascular disease in chronic renal failure: pathophysiologic aspects","volume":"16","author":"London","year":"2003","journal-title":"Semin Dial"},{"key":"2026041617114949200_oeag023-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2019.07.001","article-title":"Lipid levels achieved after a first myocardial infarction and the prediction of recurrent atherosclerotic cardiovascular disease","volume":"296","author":"Ohm","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026041617114949200_oeag023-B33","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1016\/j.jacl.2024.05.009","article-title":"The role of residual inflammatory risk and LDL cholesterol in patients with in-stent restenosis undergoing percutaneous coronary intervention","volume":"18","author":"Zhang","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026041617114949200_oeag023-B34","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2019","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B35","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026041617114949200_oeag023-B36","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B37","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1093\/eurheartj\/ehae565","article-title":"Universal screening for hsCRP in patients with atherosclerotic disease: a Major therapeutic opportunity","volume":"45","author":"Liuzzo","year":"2024","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B38","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1093\/eurheartj\/ehaf174","article-title":"Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis","volume":"46","author":"Samuel","year":"2025","journal-title":"Eur Heart J"},{"key":"2026041617114949200_oeag023-B39","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/ATVBAHA.124.319980","article-title":"Novel therapeutics and upcoming clinical trials targeting inflammation in cardiovascular diseases","volume":"44","author":"Potere","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["European Heart Journal Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjopen\/advance-article-pdf\/doi\/10.1093\/ehjopen\/oeag023\/66958723\/oeag023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/2\/oeag023\/68096023\/oeag023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjopen\/article-pdf\/6\/2\/oeag023\/68096023\/oeag023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:12:03Z","timestamp":1776373923000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjopen\/article\/doi\/10.1093\/ehjopen\/oeag023\/8488690"}},"subtitle":[],"editor":[{"given":"Salvatore","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjopen\/oeag023","relation":{},"ISSN":["2752-4191"],"issn-type":[{"value":"2752-4191","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,17]]},"article-number":"oeag023"}}